Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LiveSpo Navax for Acute Rhinosinusitis and Acute Otitis Media
NCT05804123Completed
- Sponsor
- AnaBio Technologies
- Start
- Oct 2021
- Primary completion
- Apr 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of LiveSpo Navax in acute rhinosinusitis (ARS) and acute otitis media (AOM) (4 arms), sponsored by AnaBio Technologies. Primary endpoints: Changes in percentages of patients with free acute rhinosinusitis symptoms at Day 7 and Changes in percentages of patients with free acute otitis media symptoms at Day 3. Started Oct 2021; status: completed.
02
Drugs
LiveSpo Navax
03
Conditions
acute rhinosinusitis (ARS)acute otitis media (AOM)
Beyond the preview
Go deeper on NCT05804123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804123.